Try a new search

Format these results:

Searched for:

keyword:diabetes

department:pediatrics

recent-years:5

school:SOM

Total Results:

93


Racial/Ethnic Differences in the Joint Effect of Edentulism and Diabetes on All-Cause Mortality Risks: A 12-Year Prospective Cohort Analysis

Qi, Xiang; Tan, Chenxin; Luo, Huabin; Plassman, Brenda L; Sloan, Frank A; Kamer, Angela R; Schwartz, Mark D; Wu, Bei
OBJECTIVES/OBJECTIVE:Edentulism and diabetes mellitus (DM) are frequently seen among older adults. However, the joint effect of edentulism and DM on mortality was understudied. We aim to examine the joint effect of edentulism and DM on all-cause mortality and to what extent the joint effect varies by race/ethnicity. METHODS:Analysis of US Health and Retirement Study (HRS) data (2006-2018) included 11,813 non-Hispanic Whites, 2216 non-Hispanic Blacks, and 1337 Hispanics aged ≥ 50 years old. Mortality data came from the National Death Index or HRS surveys. Edentulism was self-reported and DM was determined by self-reported diagnosis, medication use, or glycosylated hemoglobin. Cox proportional-hazard models with inverse probability treatment weighting were applied. RESULTS:During mean follow-up of 9.6 years, 2874 Whites, 703 Blacks, and 441 Hispanics died. DM was associated with higher mortality across all groups (Whites: HR = 1.43, 95% CI = 1.25-1.64; Blacks: HR = 1.62, 95% CI = 1.28-2.04; Hispanics: HR = 1.46, 95% CI = 1.07-1.99). However, edentulism predicted higher mortality only in Whites (HR = 1.65, 95% CI = 1.51-1.80). Having both conditions showed highest mortality risk in all groups (Whites: HR = 2.31, 95% CI = 1.56-3.42; Blacks: HR = 1.94, 95% CI = 1.45-2.59; Hispanics: HR = 1.77, 95% CI = 1.16-2.70), with a significant additive interaction observed only in Whites (relative excess risk due to interaction = 0.22, p < 0.05). CONCLUSIONS:DM and edentulism pose an additive risk for mortality in Whites, and there are racial/ethnic differences in edentulism-related mortality.
PMID: 40528296
ISSN: 1752-7325
CID: 5870912

Implementation and Evaluation of a Best Practice Advisory to Reduce Inequities in Technology Use for People With Type 1 Diabetes: Protocol for a Mixed Methods, Nonrandomized Controlled Trial

Mathioudakis, Nestoras; Wolf, Risa; Choudhary, Abha; Davis, Georgia; Gallagher, Mary Pat; Gupta, Meenal; Kamboj, Manmohan; Rioles, Nicole; Ospelt, Emma; Thapa, Susan; Weinstock, Ruth S; Wright, Trevon; Ebekozien, Osagie
BACKGROUND:Continuous advancements in diabetes technologies have improved self-management for people with type 1 diabetes. Continuous glucose monitoring and automated insulin delivery systems have enhanced the quality of life and glycemic outcomes while reducing severe hypoglycemia and diabetes ketoacidosis hospitalizations. Despite these benefits, racial inequities in the use of advanced diabetes technology (ADT) persist. OBJECTIVE:This study aims to develop and evaluate a best practice advisory (BPA) within the electronic medical record (EMR) to reduce racial and ethnic disparities in ADT use. We hypothesize that an EMR-based BPA designed to standardize the prescribing of ADTs will minimize racial and ethnic disparities in ADT adoption or progression in use among pediatric and adult people with type 1 diabetes. METHODS:The Best Practice Advisories to Reduce Inequities in Technology Use (BPA-TECH) study will use a nonrandomized matched pair intervention design. Phase 1 will use qualitative methods to develop and refine the BPA, including focus groups and surveys of health care providers and people with type 1 diabetes or their caregivers. Phase 2 will evaluate the effectiveness of the BPA through a controlled before-after study of people with type 1 diabetes seen at 7 T1D Exchange Quality Improvement Collaborative (T1DX-QI) centers, with control people with type 1 diabetes matched from nonintervention T1DX-QI centers. The baseline and postintervention periods will be the 12 months before and 12 months after deployment of the BPA at the intervention centers, respectively. Eligibility criteria include people with type 1 diabetes aged ≥2 years with an EMR diagnosis of T1D during the baseline period. The primary outcome is the progression in ADT use from the baseline to postintervention periods. RESULTS:), severe hypoglycemic events, and diabetes ketoacidosis events will be collected via the T1DX-QI coordinating center. The study is powered to detect a between-group difference of 15% in the proportion of patients in the intervention and control groups in meeting the primary endpoint. We anticipate the completion of this study by May 2027. CONCLUSIONS:The BPA-TECH study aims to leverage health IT to address racial and ethnic disparities in ADT use among people with type 1 diabetes. By standardizing the approach to ADT prescribing for people with type 1 diabetes, the BPA-TECH has the potential to promote equity in diabetes management and improve clinical outcomes. The outcomes of this study will inform future efforts to reduce health care disparities. TRIAL REGISTRATION/BACKGROUND:ClinicalTrials.gov NCT06931275; https://clinicaltrials.gov/search?term=NCT06931275. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)/UNASSIGNED:DERR1-10.2196/71038.
PMID: 40434817
ISSN: 1929-0748
CID: 5855392

From Childhood Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hyperlipidemia Through Oxidative Stress During Childhood

Accacha, Siham; Barillas-Cerritos, Julia; Srivastava, Ankita; Ross, Frances; Drewes, Wendy; Gulkarov, Shelly; De Leon, Joshua; Reiss, Allison B
BACKGROUND/OBJECTIVES/OBJECTIVE:Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is rapidly becoming the most prevalent form of chronic liver disease in both pediatric and adult populations. It encompasses a wide spectrum of liver abnormalities, ranging from simple fat accumulation to severe conditions such as inflammation, fibrosis, cirrhosis, and liver cancer. Major risk factors for MASLD include obesity, insulin resistance, type 2 diabetes, and hypertriglyceridemia. METHODS:This narrative review employed a comprehensive search of recent literature to identify the latest studies on the relationship between MAFLD and obesity, the health consequences and the latest treatment options to prevent long-term damage to the liver and other organs. Additionally, the article presents perspectives on diagnostic biomarkers. RESULTS:Childhood obesity is linked to a multitude of comorbid conditions and remains a primary risk factor for adult obesity. This abnormal fat accumulation is known to have long-term detrimental effects into adulthood. Scientific evidence unequivocally demonstrates the role of obesity-related conditions, such as insulin resistance, dyslipidemia, and hyperglycemia, in the development and progression of MASLD. Oxidative stress, stemming from mitochondrial dysfunction, is a leading factor in MASLD. This review discusses the interconnections between oxidative stress, obesity, dyslipidemia, and MASLD. CONCLUSIONS:Atherogenic dyslipidemia, oxidative stress, inflammation, insulin resistance, endothelial dysfunction, and cytokines collectively contribute to the development of MASLD. Potential treatment targets for MASLD are focused on prevention and the use of drugs to address obesity and elevated blood lipid levels.
PMCID:12113454
PMID: 40422865
ISSN: 2218-1989
CID: 5855182

Considerations for more actionable consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Reply to Mallone R [letter] [Letter]

Phillip, Moshe; Achenbach, Peter; Addala, Ananta; Albanese-O'Neill, Anastasia; Battelino, Tadej; Bell, Kirstine J; Besser, Rachel E J; Bonifacio, Ezio; Colhoun, Helen M; Couper, Jennifer J; Craig, Maria E; Danne, Thomas; de Beaufort, Carine; Dovc, Klemen; Dutta, Sanjoy; Ebekozien, Osagie; Elding Larsson, Helena; Frohnert, Brigitte I; Gallagher, Mary P; Greenbaum, Carla J; Griffin, Kurt J; Hagopian, William; Haller, Michael J; Hendriks, Emile; Holt, Richard I G; Ismail, Heba M; Jacobsen, Laura M; Kolb, Leslie E; Kordonouri, Olga; Lange, Karin; Lash, Robert W; Lernmark, Åke; Libman, Ingrid; Lundgren, Markus; Maahs, David M; Marcovecchio, M Loredana; Mathieu, Chantal; Oron, Tal; Patil, Shivajirao P; Rewers, Marian J; Rich, Stephen S; Schatz, Desmond A; Schulman-Rosenbaum, Rifka; Simmons, Kimber M; Sims, Emily K; Skyler, Jay S; Speake, Cate; Steck, Andrea K; Tonyushkina, Ksenia N; Veijola, Riitta; Wentworth, John M; Wherrett, Diane K; Wood, Jamie R; Ziegler, Anette-Gabriele; DiMeglio, Linda A
PMID: 39934371
ISSN: 1432-0428
CID: 5793442

Racial/Ethnic Differences in the Joint Effect of Edentulism and Diabetes on All-Cause Mortality Risks: A 12-Year Prospective Cohort Analysis

Qi, Xiang; Tan, Chenxin; Luo, Huabin; Plassman, Brenda L.; Sloan, Frank A.; Kamer, Angela R.; Schwartz, Mark D.; Wu, Bei
ISI:001510430800001
ISSN: 0022-4006
CID: 5873582

Reducing Requirements for Insulin Pump Referral Improves Pump Initiation for Publicly Insured Children and Youth With Type 1 Diabetes

Miyazaki, Brian; Baldwin, Jennifer; Connard, James; Aceves, Jose; Alula, Jessica Llovido; Berman, Casey; Ferris, Jessica; Miller, Debra; Odugbesan, Ori; La Banca Barber, Rebecca Ortiz; Chao, Lily C
Quality Improvement Success Stories are published by the American Diabetes Association in collaboration with the American College of Physicians and the National Diabetes Education Program. This series is intended to highlight best practices and strategies from programs and clinics that have successfully improved the quality of care for people with diabetes or related conditions. Each article in the series is reviewed and follows a standard format developed by the editors of Clinical Diabetes. The following article describes a quality improvement initiative to reduce barriers to insulin pump initiation for people with type 1 diabetes.
PMCID:11739347
PMID: 39829705
ISSN: 0891-8929
CID: 5802062

Diabetes Centers' Participation in the T1D Exchange Quality Improvement Collaborative Advances Health Equity and Clinical Outcomes

Accacha, Siham; Mungmode, Ann; Benzoni, Lori; Rioles, Nicole; Aleppo, Grazia; Steenkamp, Devin; Levy, Carol J; Antal, Zoltan; Wong, Jenise C; Nelson, Grace; Alonso, G Todd; Ebekozien, Osagie
As the learning health network known as the T1D Exchange Quality Improvement Collaborative (T1DX-QI) has expanded on a significant scale to provide care for more than 120,000 people since its inception in 2016, assessing the quality improvement (QI) culture and monitoring clinical outcome improvements of participating centers has become vital to understanding the network's progress and success. Centers participating in the T1DX-QI complete regular QI culture self-assessments to quantify four evidence-based areas of culture: QI team structure, QI foundation, QI capacity, and QI success. This study builds on a previous baseline analysis to demonstrate self-reported improvements in T1DX-QI centers' QI culture from 2021 to 2022 and summarizes QI successes experienced by participating centers.
PMCID:11739363
PMID: 39829700
ISSN: 0891-8929
CID: 5802052

Developmental Origins of Non-Communicable Chronic Diseases: Role of Fetal Undernutrition and Gut Dysbiosis in Infancy

Chandra, Manju
There is an increasing prevalence of non-communicable chronic diseases (NCCDs) like obesity, metabolic syndrome, type 2 diabetes mellitus (T2DM), hypertension, allergic asthma, and neuro-developmental/psychiatric problems in many parts of the world. A suboptimal lifestyle as an adult is often blamed for the occurrence of NCCDs. This review discusses the developmental origin of health and disease theory and how suboptimal nutrition in intrauterine life and the establishment of a suboptimal gut microbiome during infancy can influence the predisposition to NCCDs.
PMCID:11592819
PMID: 39594962
ISSN: 2227-9067
CID: 5783212

EXPRESS: Plasma from Type 1 Diabetes Patients Promotes Pro-atherogenic Cholesterol Transport in Human Macrophages

Accacha, Siham Acacha; Kasselman, Lora J; Mejia-Corletto, Jorge; Srivastava, Ankita; Voloshyna, Iryna; Renna, Heather A; De Leon, Joshua; Levine, Robert L; Reiss, Allison Bethanne
Hyperglycemia, one of the major risk factors for atherosclerosis, leads to the accumulation of Advanced glycation end products (AGEs), contributing to cardiovascular complications. Such accumulation may accelerate the progression of vascular disease in patients with diabetes. Reverse cholesterol transport (RCT) protein, ATP-binding membrane cassette transporters A1 and G1 (ABCA1 and ABCG1) and cholesterol 27-hydroxylase facilitate cholesterol removal from macrophages. AGE inhibits reverse cholesterol transport by reducing the expression of ABCA1 and ABCG1. This study aimed to evaluate whether plasma from poorly controlled adolescents with type 1 diabetes (T1D) disrupts cholesterol homeostasis in human monocytes/macrophages. Twenty healthy controls (HC) and 20 patients with T1DM, 10 to 19 years old, were enrolled. Naïve THP-1 macrophages were exposed to plasma from each HC and patient with T1D. Following incubation, mRNA for cholesterol efflux (ABCA1, ABCG1, 27-hydroxylase) and cholesterol uptake (CD36, ScR-A1, lectin oxidized low-density lipoprotein (LOX)-1, CXCL16) were isolated. Foam cell formation was quantified to confirm the pro-atherogenic effects of T1D plasma on macrophages. Results showed that T1D plasma had an elevated level of CML-modified proteins and upregulated CXCL16 and, to a lesser degree, ScR-A1. This change in gene expression in the presence of T1D plasma is associated with increased lipid accumulation and foam cell formation by THP-1 macrophages. In our study, these cells' uptake of an AGE product occurred mainly through the SR-A1 and CXCL16 receptors, leading to increased intracellular oxidized LDL. We conclude that AGEs may contribute to accelerated atherosclerosis in diabetes through effects on both forward and reverse cholesterol movement.
PMID: 39417428
ISSN: 1708-8267
CID: 5718702

Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes

Phillip, Moshe; Achenbach, Peter; Addala, Ananta; Albanese-O'Neill, Anastasia; Battelino, Tadej; Bell, Kirstine J; Besser, Rachel E J; Bonifacio, Ezio; Colhoun, Helen M; Couper, Jennifer J; Craig, Maria E; Danne, Thomas; de Beaufort, Carine; Dovc, Klemen; Driscoll, Kimberly A; Dutta, Sanjoy; Ebekozien, Osagie; Larsson, Helena Elding; Feiten, Daniel J; Frohnert, Brigitte I; Gabbay, Robert A; Gallagher, Mary P; Greenbaum, Carla J; Griffin, Kurt J; Hagopian, William; Haller, Michael J; Hendrieckx, Christel; Hendriks, Emile; Holt, Richard I G; Hughes, Lucille; Ismail, Heba M; Jacobsen, Laura M; Johnson, Suzanne B; Kolb, Leslie E; Kordonouri, Olga; Lange, Karin; Lash, Robert W; Lernmark, Ã…ke; Libman, Ingrid; Lundgren, Markus; Maahs, David M; Marcovecchio, M Loredana; Mathieu, Chantal; Miller, Kellee M; O'Donnell, Holly K; Oron, Tal; Patil, Shivajirao P; Pop-Busui, Rodica; Rewers, Marian J; Rich, Stephen S; Schatz, Desmond A; Schulman-Rosenbaum, Rifka; Simmons, Kimber M; Sims, Emily K; Skyler, Jay S; Smith, Laura B; Speake, Cate; Steck, Andrea K; Thomas, Nicholas P B; Tonyushkina, Ksenia N; Veijola, Riitta; Wentworth, John M; Wherrett, Diane K; Wood, Jamie R; Ziegler, Anette-Gabriele; DiMeglio, Linda A
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programmes are being increasingly emphasised. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb+) children and adults who are at risk of (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in non-specialised settings. To inform this monitoring, JDRF in conjunction with international experts and societies developed consensus guidance. Broad advice from this guidance includes the following: (1) partnerships should be fostered between endocrinologists and primary-care providers to care for people who are IAb+; (2) when people who are IAb+ are initially identified there is a need for confirmation using a second sample; (3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; (4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; (5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and (6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasises significant unmet needs for further research on early-stage type 1 diabetes to increase the rigour of future recommendations and inform clinical care.
PMID: 38910151
ISSN: 1432-0428
CID: 5719142